<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528411</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00048</org_study_id>
    <nct_id>NCT00528411</nct_id>
  </id_info>
  <brief_title>A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin</brief_title>
  <official_title>A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet
      medication, affects platelets. Anti-platelet agents are medications that block the formation
      of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding,
      but when they form inside the arteries their formation is linked to a risk of medical
      problems such as heart attack and stroke. This study investigated how long it takes for
      Ticagrelor to begin working and how long it takes for it to stop working after the last dose
      of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment
      for preventing blood clots, and placebo plus Aspirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose</measure>
    <time_frame>At 2 hours after first dose of study drug</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug</measure>
    <time_frame>4 to 72 Hours after last dose of study drug</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose</measure>
    <time_frame>0.5 hours after first dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose</measure>
    <time_frame>1 hour after first dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose</measure>
    <time_frame>4 hours after first dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose</measure>
    <time_frame>8 hours after first dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose</measure>
    <time_frame>24 hours after first dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose</measure>
    <time_frame>0 hour before last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose</measure>
    <time_frame>2 hours after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose</measure>
    <time_frame>4 hours after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose</measure>
    <time_frame>8 hours after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose</measure>
    <time_frame>24 hours after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose</measure>
    <time_frame>48 hours after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose</measure>
    <time_frame>120 hours - Day 5 after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose</measure>
    <time_frame>168 hours - Day 7 after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose</measure>
    <time_frame>240 hours - Day 10 after last dose</time_frame>
    <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline</time_frame>
    <description>FEV1 is measured by Spirometry, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Post 6-week Treatment: FEV1</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>FEV1 is measured by Spirometry, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline</time_frame>
    <description>FVC is measured by Spirometry, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Post 6-week Treatment: FVC</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>FVC is measured by Spirometry, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)</measure>
    <time_frame>Baseline</time_frame>
    <description>FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)</measure>
    <time_frame>Baseline</time_frame>
    <description>FEF25-75 is measured by Spirometry, the unit is Liter/Second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>FEF25-75 is measured by Spirometry, the unit is Liter/Second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)</measure>
    <time_frame>Baseline</time_frame>
    <description>FRC is measured by Body Box Plethysmography, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: FRC</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>FRC is measured by Body Box Plethysmography, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)</measure>
    <time_frame>Baseline</time_frame>
    <description>TLC is measured by Body Box Plethysmography, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: TLC</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>TLC is measured by Body Box Plethysmography, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Residual Volume (RV)</measure>
    <time_frame>Baseline</time_frame>
    <description>RV is measured by Body Box Plethysmography, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: RV</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>RV is measured by Body Box Plethysmography, the unit is Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)</measure>
    <time_frame>Baseline</time_frame>
    <description>VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: VE</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)</measure>
    <time_frame>Baseline</time_frame>
    <description>RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: RR</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)</measure>
    <time_frame>Baseline</time_frame>
    <description>VT is measured by Body Box Plethysmography, the unit is Liter/Minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: VT</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>VT is measured by Body Box Plethysmography, the unit is Liter/Minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)</measure>
    <time_frame>Baseline</time_frame>
    <description>DLCOSB is measured by Body Box Plethysmography, the unit is Percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>DLCOSB is measured by Body Box Plethysmography, the unit is Percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)</measure>
    <time_frame>Baseline</time_frame>
    <description>EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: EF</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>Baseline</time_frame>
    <description>NT-proBNP is measured by clinical lab, the unit is pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>NT-proBNP is measured by clinical lab, the unit is pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)</measure>
    <time_frame>Baseline</time_frame>
    <description>SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Parameters Post 6-week Treatment: SpO2</measure>
    <time_frame>6-week post treatment</time_frame>
    <description>SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin + clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin + Ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor Tablets</intervention_name>
    <description>Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel (over encapsulated) capsule</intervention_name>
    <description>Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Clopidogrel Bisulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Tablets</intervention_name>
    <description>Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented stable Coronary Artery Disease (stable angina, previous MI history,
             previous history of revascularization);

          -  Females of child bearing potential must have a negative pregnancy test prior to
             receiving study drug and be willing to use a hormonal contraceptive in addition to
             double barrier contraception

        Exclusion Criteria:

          -  History of Acute Coronary Syndromes within 12 months of screening or need for
             revascularization (angioplasty or Coronary Artery Bypass Graft (CABG))

          -  History of liver or kidney disease

          -  Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high
             blood pressure, low platelet count, recent major trauma

          -  History of intolerance or allergy to Aspirin or clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Sager, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Gurbel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Platelet &amp; Thrombosis Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>January 27, 2011</results_first_submitted>
  <results_first_submitted_qc>December 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2012</results_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>CAD</keyword>
  <keyword>heart attack</keyword>
  <keyword>stable angina</keyword>
  <keyword>Stable coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg Twice Daily (bd), plus clopidogrel placebo loading and Once Daily (od) maintenance doses</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 600 mg loading dose followed by 75 mg Twice Daily (od), plus ticagrelor placebo loading and Once Daily (bd) maintenance doses</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg Twice Daily (bd), plus clopidogrel placebo loading and Once Daily (od) maintenance doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Enrolment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prior commitment medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus Clopidogrel placebo loading and od maintenance doses</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="9.10"/>
                    <measurement group_id="B2" value="65.4" spread="7.98"/>
                    <measurement group_id="B3" value="63.9" spread="8.32"/>
                    <measurement group_id="B4" value="63.8" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>At 2 hours after first dose of study drug</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.15" lower_limit="80.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="31.05" lower_limit="10.3" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.</description>
        <time_frame>4 to 72 Hours after last dose of study drug</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage/Hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.037" spread="0.076" lower_limit="0.076"/>
                    <measurement group_id="O2" value="-0.482" spread="0.055" lower_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>0.5 hours after first dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.39" lower_limit="3.0" upper_limit="66.4"/>
                    <measurement group_id="O2" value="4.71" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>1 hour after first dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.71" lower_limit="72.6" upper_limit="99.4"/>
                    <measurement group_id="O2" value="15.83" lower_limit="0.0" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>4 hours after first dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.39" lower_limit="84.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="40.87" lower_limit="16.6" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>8 hours after first dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.99" lower_limit="81.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="46.90" lower_limit="20.4" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>24 hours after first dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.29" lower_limit="62.9" upper_limit="98.4"/>
                    <measurement group_id="O2" value="49.64" lower_limit="17.7" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>0 hour before last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.53" lower_limit="56.5" upper_limit="98.3"/>
                    <measurement group_id="O2" value="51.75" lower_limit="32.8" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>2 hours after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.49" lower_limit="83.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="62.96" lower_limit="35.2" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>4 hours after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.10" lower_limit="80.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="61.80" lower_limit="35.2" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>8 hours after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.31" lower_limit="77.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="61.31" lower_limit="39.0" upper_limit="61.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>24 hours after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.18" lower_limit="39.1" upper_limit="85.4"/>
                    <measurement group_id="O2" value="53.91" lower_limit="35.1" upper_limit="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>48 hours after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.94" lower_limit="14.3" upper_limit="51.5"/>
                    <measurement group_id="O2" value="45.79" lower_limit="19.4" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>72 hours after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76" lower_limit="0.0" upper_limit="34.5"/>
                    <measurement group_id="O2" value="21.09" lower_limit="10.2" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>120 hours - Day 5 after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.2"/>
                    <measurement group_id="O2" value="21.15" lower_limit="0.0" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>168 hours - Day 7 after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="11.7"/>
                    <measurement group_id="O2" value="6.32" lower_limit="0.0" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose</title>
        <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
        <time_frame>240 hours - Day 10 after last dose</time_frame>
        <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose</title>
          <description>IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.</description>
          <population>Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>FEV1 is measured by Spirometry, the unit is Liter.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>FEV1 is measured by Spirometry, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.725"/>
                    <measurement group_id="O2" value="2.71" spread="0.791"/>
                    <measurement group_id="O3" value="2.94" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Post 6-week Treatment: FEV1</title>
        <description>FEV1 is measured by Spirometry, the unit is Liter.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Post 6-week Treatment: FEV1</title>
          <description>FEV1 is measured by Spirometry, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.712"/>
                    <measurement group_id="O2" value="2.74" spread="0.751"/>
                    <measurement group_id="O3" value="2.95" spread="0.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)</title>
        <description>FVC is measured by Spirometry, the unit is Liter.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)</title>
          <description>FVC is measured by Spirometry, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="0.903"/>
                    <measurement group_id="O2" value="3.73" spread="1.082"/>
                    <measurement group_id="O3" value="4.03" spread="0.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Post 6-week Treatment: FVC</title>
        <description>FVC is measured by Spirometry, the unit is Liter.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Post 6-week Treatment: FVC</title>
          <description>FVC is measured by Spirometry, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="0.933"/>
                    <measurement group_id="O2" value="3.78" spread="1.029"/>
                    <measurement group_id="O3" value="3.98" spread="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)</title>
        <description>FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)</title>
          <description>FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.01" spread="7.049"/>
                    <measurement group_id="O2" value="73.04" spread="6.764"/>
                    <measurement group_id="O3" value="73.13" spread="7.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio</title>
        <description>FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio</title>
          <description>FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.71" spread="5.694"/>
                    <measurement group_id="O2" value="72.84" spread="6.371"/>
                    <measurement group_id="O3" value="74.27" spread="7.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)</title>
        <description>FEF25-75 is measured by Spirometry, the unit is Liter/Second.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)</title>
          <description>FEF25-75 is measured by Spirometry, the unit is Liter/Second.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="1.251"/>
                    <measurement group_id="O2" value="2.70" spread="1.208"/>
                    <measurement group_id="O3" value="2.50" spread="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75</title>
        <description>FEF25-75 is measured by Spirometry, the unit is Liter/Second.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75</title>
          <description>FEF25-75 is measured by Spirometry, the unit is Liter/Second.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="1.289"/>
                    <measurement group_id="O2" value="2.67" spread="1.156"/>
                    <measurement group_id="O3" value="2.91" spread="1.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)</title>
        <description>FRC is measured by Body Box Plethysmography, the unit is Liter.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)</title>
          <description>FRC is measured by Body Box Plethysmography, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.827"/>
                    <measurement group_id="O2" value="2.89" spread="0.876"/>
                    <measurement group_id="O3" value="2.91" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: FRC</title>
        <description>FRC is measured by Body Box Plethysmography, the unit is Liter.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: FRC</title>
          <description>FRC is measured by Body Box Plethysmography, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.723"/>
                    <measurement group_id="O2" value="2.79" spread="0.857"/>
                    <measurement group_id="O3" value="2.75" spread="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)</title>
        <description>TLC is measured by Body Box Plethysmography, the unit is Liter.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)</title>
          <description>TLC is measured by Body Box Plethysmography, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="1.299"/>
                    <measurement group_id="O2" value="5.83" spread="1.401"/>
                    <measurement group_id="O3" value="6.10" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: TLC</title>
        <description>TLC is measured by Body Box Plethysmography, the unit is Liter.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: TLC</title>
          <description>TLC is measured by Body Box Plethysmography, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="1.182"/>
                    <measurement group_id="O2" value="5.85" spread="1.396"/>
                    <measurement group_id="O3" value="5.96" spread="1.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Residual Volume (RV)</title>
        <description>RV is measured by Body Box Plethysmography, the unit is Liter.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Residual Volume (RV)</title>
          <description>RV is measured by Body Box Plethysmography, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.780"/>
                    <measurement group_id="O2" value="2.01" spread="0.643"/>
                    <measurement group_id="O3" value="1.91" spread="0.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: RV</title>
        <description>RV is measured by Body Box Plethysmography, the unit is Liter.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: RV</title>
          <description>RV is measured by Body Box Plethysmography, the unit is Liter.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.621"/>
                    <measurement group_id="O2" value="1.97" spread="0.559"/>
                    <measurement group_id="O3" value="1.90" spread="0.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)</title>
        <description>VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)</title>
          <description>VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liter/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.92" spread="3.950"/>
                    <measurement group_id="O2" value="12.17" spread="3.552"/>
                    <measurement group_id="O3" value="12.06" spread="4.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: VE</title>
        <description>VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: VE</title>
          <description>VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liter/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.69" spread="3.582"/>
                    <measurement group_id="O2" value="13.14" spread="5.515"/>
                    <measurement group_id="O3" value="11.45" spread="3.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)</title>
        <description>RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)</title>
          <description>RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Breaths/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.79" spread="2.433"/>
                    <measurement group_id="O2" value="14.15" spread="2.743"/>
                    <measurement group_id="O3" value="15.5" spread="1.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: RR</title>
        <description>RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: RR</title>
          <description>RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Breaths/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.21" spread="2.817"/>
                    <measurement group_id="O2" value="15.10" spread="2.303"/>
                    <measurement group_id="O3" value="14.91" spread="0.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)</title>
        <description>VT is measured by Body Box Plethysmography, the unit is Liter/Minute.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)</title>
          <description>VT is measured by Body Box Plethysmography, the unit is Liter/Minute.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.326"/>
                    <measurement group_id="O2" value="0.89" spread="0.322"/>
                    <measurement group_id="O3" value="0.89" spread="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: VT</title>
        <description>VT is measured by Body Box Plethysmography, the unit is Liter/Minute.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: VT</title>
          <description>VT is measured by Body Box Plethysmography, the unit is Liter/Minute.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.264"/>
                    <measurement group_id="O2" value="0.93" spread="0.393"/>
                    <measurement group_id="O3" value="0.83" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)</title>
        <description>DLCOSB is measured by Body Box Plethysmography, the unit is Percent.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)</title>
          <description>DLCOSB is measured by Body Box Plethysmography, the unit is Percent.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.00" spread="8.673"/>
                    <measurement group_id="O2" value="17.29" spread="10.891"/>
                    <measurement group_id="O3" value="15.83" spread="6.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB</title>
        <description>DLCOSB is measured by Body Box Plethysmography, the unit is Percent.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB</title>
          <description>DLCOSB is measured by Body Box Plethysmography, the unit is Percent.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.38" spread="8.090"/>
                    <measurement group_id="O2" value="16.53" spread="8.286"/>
                    <measurement group_id="O3" value="16.09" spread="7.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)</title>
        <description>EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)</title>
          <description>EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.96" spread="9.302"/>
                    <measurement group_id="O2" value="61.91" spread="7.624"/>
                    <measurement group_id="O3" value="59.92" spread="10.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: EF</title>
        <description>EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: EF</title>
          <description>EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.70" spread="8.430"/>
                    <measurement group_id="O2" value="62.38" spread="7.096"/>
                    <measurement group_id="O3" value="60.73" spread="9.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)</title>
        <description>NT-proBNP is measured by clinical lab, the unit is pg/mL.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)</title>
          <description>NT-proBNP is measured by clinical lab, the unit is pg/mL.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.34" spread="184.298"/>
                    <measurement group_id="O2" value="185.98" spread="227.141"/>
                    <measurement group_id="O3" value="145.41" spread="144.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP</title>
        <description>NT-proBNP is measured by clinical lab, the unit is pg/mL.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP</title>
          <description>NT-proBNP is measured by clinical lab, the unit is pg/mL.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.88" spread="170.347"/>
                    <measurement group_id="O2" value="214.43" spread="313.429"/>
                    <measurement group_id="O3" value="140.68" spread="145.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)</title>
        <description>SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)</title>
          <description>SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.59" spread="1.570"/>
                    <measurement group_id="O2" value="96.78" spread="1.949"/>
                    <measurement group_id="O3" value="97.58" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiopulmonary Parameters Post 6-week Treatment: SpO2</title>
        <description>SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.</description>
        <time_frame>6-week post treatment</time_frame>
        <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Parameters Post 6-week Treatment: SpO2</title>
          <description>SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.</description>
          <population>Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.73" spread="1.239"/>
                    <measurement group_id="O2" value="97.35" spread="1.262"/>
                    <measurement group_id="O3" value="98.56" spread="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Poor R-Wave Progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Tendency To Bruise</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

